Treatment of arthritis
The treatment of arthritis by corticosteroids is often hampered by a low efficacy, limited duration and multiple off-target toxicities. The value of CriPec® dexamethasone lies in the extensive and sustained suppression of inflammation without corticosteroid-related adverse effects. This effect does not seem to be specific for CriPec dexamethasone, but is expected to hold true for all corticosteroids.
CriPec dexamethasone demonstrated a superior efficacy in arthritis models in both mice and rats, as a result of the enhanced accumulation at the site of inflammation combined with well-controlled drug release, as compared to conventional dexamethasone treatment.
Data show superior efficacy combined with excellent tolerability results. This was confirmed by uCT images, bone mineral density measurements and histology.